Evidence availability for 1-year obesity treatment-initiation decisions: an estimand-aligned Bayesian longitudinal network meta-analysis
Background Obesity pharmacotherapy strategies differ in maintenance dose, titration, and lifestyle support, but existing syntheses primarily compare drugs rather than treatment-initiation decisions. We assessed 1-year weight reduction, permanent discontinuation, and incremental dose-related trade-offs while mapping the availability of eligible trial evidence. Methods We searched eight databases and two trial registries through October 2026 for randomised trials (at least 12 weeks) of obesity pharmacotherapy initiation in adults with overweight or obesity. Maintenance, withdrawal, and switching trials were excluded. Two reviewers independently selected studies, extracted data, and assessed bias and certainty. Bayesian longitudinal network meta-analysis estimated treatment-policy-compatible weight change at 52 weeks. Additional analyses examined discontinuation, dose escalation, titration, lifestyle support, and diabetes-related attenuation. The study was registered with PROSPERO (CRD420261532130). Findings We included 180 reports from 178 trials (196 randomisation units; 81,014 participants). Only 78 units reached the 1-year evidence layer, 50 informed the primary longitudinal model in adults without diabetes, and 45 of 160 target strategies had non-extrapolated 52-week estimates. Placebo-adjusted weight reductions were greatest with retatrutide 12 mg (-19.80 percentage points, 95% CrI -21.81 to -17.78), tirzepatide 15 mg (-16.87, -18.07 to -15.51), and cagrilintide-semaglutide 2.4/2.4 mg (-16.37, -18.10 to -14.70). Only tirzepatide 15 mg and semaglutide 2.4 mg had high-certainty evidence. Thirteen of 32 strategies increased adverse-event-related permanent discontinuation versus placebo; none increased all-cause discontinuation. Five of 22 adjacent dose steps had at least 0.80 probability of adding more than 2 percentage points of weight reduction. Eight 1-year titration contrasts and three trials of randomised lifestyle-support increments were identified. Weight reduction in adults with type 2 diabetes was 62% of that without diabetes (ratio 0.62, 95% CI 0.58-0.66). Interpretation Evidence directly supporting 1-year obesity treatment-initiation decisions remains limited. Higher-dose and multi-receptor strategies achieve substantial weight reduction, but certainty and discontinuation trade-offs vary. Better treatment-policy reporting and randomised evidence on titration and lifestyle support are needed.
Authors
- Minhui Dai (ORCID: https://orcid.org/0000-0001-5026-8716)
- Dongliang Liu (ORCID: https://orcid.org/0000-0002-8055-1157)
- Zhuying Xia
- Xinbo Yin
- Xiaokai Wang
- Guoqing Huang
- Xiangmin Li
Institutions
- Xiangya Hospital Central South University (CN)
Publication Details
- Journal
- medRxiv
- Published
- 2026-11-13
- DOI
- https://doi.org/10.64898/2026.11.13.26367524
- Primary Topic
- Pharmacology and Obesity Treatment
- Type
- preprint